| Objective:This work aimed to investigate the expression levels of CXCL12/CXCR4,CD44and CD133in adenoid cystic carcinoma and to explore its relationshipwith clinicopathologic characteristics and clinical outcomes of ACC.Method:(1) Clinical data of62patients with ACC were collected andretrospectively analyzed. The diagnoses of all cases were pathologicallyconfirmed.(2) The expression levels of CXCL12, CXCR4and CD44, CD133inaffected tissue was detected immunohistochemically in62cases of ACC.(3) Both of the four factors and clinicalpathology factors were processed inaccordance with the Kaplan–Meier method and the COX regression model.Result:(1) The positive rates of CXCL12, CXCR4and CD44, CD133expressionwere54.8%(34/62),77.42%(48/62),74.19%(46/62) and72.58%(45/62)respectively.(2) Expression of CXCL12, CXCR4, and CD44, CD133significantly differed between different staining degrees (P<0.05).(3) It is showed that multivariate analysis indicated CXCR4expression,clinical stage, histological differentiation, metastasis/recurrence influenced ACCindependently.Conclusion:The expression of CXCL12/CXCR4and CD44, CD133may be correlatedwith the malignancy of ACC. It could be the predictors that CXCR4expression,clinical stage, metastasis/recurrence, histological differentiation can indicate theprognosis of ACC. |
PDF Full Text Request